Vertaling van "Evidence-based medicine " (Engels → Nederlands) :

evidence-based approach in primary care | evidence-based medicine in general practice | evidence-based approach in general practice | evidence-based approach in medical care

evidence-based radiography methods | evidence-based radiography process | evidence-based radiography practice | evidence-based radiography praxis

evidence-based nursing care | nursing care based on recent research developments | evidence-based nursing care | evidence-based nursing principles

policymaking [ evidence-based policymaking | interactive policymaking | IPM | policy development | policy formulation ]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

Hospital-based outpatient family medicine clinic

Specific activities shall include: understanding the determinants of health (including nutrition, physical activity and gender, and environmental, socio-economic, occupational and climate-related factors); improving health promotion and disease prevention; understanding disease and improving diagnosis and prognosis; developing effective prevention and screening programmes and improving the assessment of disease susceptibility; improving the surveillance of infectious diseases and preparedness for combating epidemics and emerging diseases; developing new and better preventive and therapeutic vaccines and drugs; using in-silico medicine for improving disea ...[+++]se management and prediction; developing regenerative medicine and adapted treatments, and treating disease, including palliative medicine; transferring knowledge to clinical practice and scalable innovation actions; improving health information and better collection and use of health cohort and administrative data; standardised data analysis and techniques; active ageing, and independent and assisted living; individual awareness and empowerment for self-management of health; promotion of integrated care, including psychosocial aspects; improving scientific tools and methods to support policy making and regulatory needs; optimising the efficiency and effectiveness of healthcare provision; and reducing health disparities and inequalities by evidence-based decision making and dissemination of best practice and by innovative technologies and approaches.

CONSIDERING that multinational clinical research is currently hampered by the fragmentation of health and legislative systems in Europe, an obstacle for multinational cooperation in investigator driven, as well as industry-sponsored clinical research (particularly in the biotechnology and medical device sectors), European countries must unlock latent scientific potential and access to patients and expertise, thus strengthening the competitiveness of Europe in clinical science and its attractiveness for the development of preventive, diagnostic and therapeutic procedures — this is of particular importance for rare diseases, paediatrics, personalised treatments, for the development of biotherapy, and for independent clinical trials that are pivotal instru ...[+++]ments for evidence-based medicine.

CONSIDERING that multinational clinical research is currently hampered by the fragmentation of health and legislative systems in Europe, an obstacle for multinational cooperation in investigator driven, as well as industry-sponsored clinical research (particularly in the biotechnology and medical device sectors), European countries must unlock latent scientific potential and access to patients and expertise, thus strengthening the competitiveness of Europe in clinical science and its attractiveness for the development of preventive, diagnostic and therapeutic procedures — this is of particular importance for rare diseases, paediatrics, personalised treatments, for the development of biotherapy, and for independent clinical trials that are pivotal instru ...[+++]ments for evidence-based medicine;

2. The sponsor shall, when applying for a low-intervention clinical trial, where the investigational medicinal product is not used in accordance with the terms of the marketing authorisation but the use of that product is evidence-based and supported by published scientific evidence on the safety and efficacy of that product, propose one of the Member States concerned where the use is evidence-based, as reporting Member State.